Cancer Screening: Detecting Cancer Signal for 50+ Cancers with One Simple Blood Draw
The Galleri test represents a revolutionary approach to cancer screening, offering something that has never been available before: the ability to screen for signals from 50+ types of cancer with a single blood test. While doctors can test individually for 5 specific cancers today, more than 70% of cancer deaths are caused by cancers without recommended screening tests. The Galleri test changes this reality by screening for a "fingerprint" of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests available today.
Cancers growing in the body shed DNA into the bloodstream. Although there are many types of cancer, the DNA fragments can act like a unique "fingerprint" of cancer. The Galleri multi-cancer screening test analyzes these cell-free DNA patterns to detect cancer signals and can even predict the tissue type or organ associated with the cancer signal—providing vital information to help guide your healthcare provider with next steps. Every time you take the test, Galleri screens more than hundreds of thousands of DNA sites in the most informative DNA regions to identify potential cancer presence before symptoms appear.
The Galleri test is specifically designed for adults with elevated cancer risk, particularly those age 50 or older. Adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50. Additional risk factors that make the test especially valuable include diabetes, obesity (BMI ≥ 30), and current or previous smoking history. The test complements, rather than replaces, routine cancer screening tests your healthcare provider recommends, offering an additional layer of protection against cancers that traditionally go undetected until symptoms appear.
In a clinical study, adding the Galleri test to recommended single-cancer screenings approximately doubled the number of cancers detected. The test has been rigorously studied in multiple clinical trials with over 20,000 participants in collaboration with leading cancer institutes including Cleveland Clinic, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center. With a simple annual blood test that provides results in about two weeks, nearly 99% of people who use the Galleri test will screen negative—exactly what you want to hear. Currently available by prescription only at a list price of $949, the Galleri test offers payment plan options and may be eligible for FSA/HSA funding, making this groundbreaking early cancer detection technology accessible to those committed to proactive health monitoring.
